Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|December 4, 2025
7 Cardiology Headlines You Missed in November 2025
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Catch up with major FDA decisions, critical conference news, and more.
Advertisement
Advertisement
November was a busy month for cardiology, between the US Food and Drug Administration’s (FDA) groundbreaking approval of plozasiran and the mountain of news presented at the American Heart Association’s Scientific Sessions 2025 in New Orleans, Louisiana. From olezarsen’s efficacy in severe hypertriglyceridemia to self-administered etripamil’s restoration of normal sinus rhythm in paroxysmal supraventricular tachycardia (PSVT), several major names in the cardiovascular pipeline made significant progress towards New Drug Application (NDA) submission last month.
Related to this article
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Advertisement
Advertisement